Maddukuri Srivarshini, Haddad Ryan R, Battula Naga Spandana, Chay Timmie, Patel Tirath, Dumaru Nabina, Mohammed Lubna
Internal Medicine, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pune, IND.
Clinical Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Cureus. 2025 Apr 24;17(4):e82912. doi: 10.7759/cureus.82912. eCollection 2025 Apr.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths, primarily associated with liver cirrhosis from factors like hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol abuse, metabolic syndrome, and genetic disorders. With the rising incidence of liver cancer, particularly in HBV-endemic regions, research into novel therapies like antibody-drug conjugates (ADCs) has gained momentum. ADCs target cancer cells by attaching cytotoxic drugs to antibodies, minimizing damage to healthy tissue. Recent clinical trials have demonstrated that ADCs targeting GPC3, such as GC33 and 32A9, show promising results in reducing tumor growth and improving patient outcomes in advanced HCC. These therapies offer a potential alternative to conventional chemotherapy, marking a significant advancement in precision oncology. This systematic review was implemented using various databases like PubMed, Google Scholar, Science Direct, EBSCO, and Public Library of Science (PLoS) using regular keywords and MeSH keywords. Eligibility criteria were restricted to free full texts in the English language, humans, and publications between 2019-2024. The exclusion criteria included languages other than English and publications before 2019. A total of 26 articles were identified, and 12 articles were selected after quality assessment.
肝细胞癌（HCC）是癌症相关死亡的主要原因，主要与乙型肝炎病毒（HBV）、丙型肝炎病毒（HCV）、酒精滥用、代谢综合征和遗传疾病等因素导致的肝硬化有关。随着肝癌发病率的上升，尤其是在HBV流行地区，对抗体药物偶联物（ADC）等新型疗法的研究势头正劲。ADC通过将细胞毒性药物与抗体结合来靶向癌细胞，将对健康组织的损害降至最低。最近的临床试验表明，靶向GPC3的ADC，如GC33和32A9，在晚期HCC中显示出减少肿瘤生长和改善患者预后的有前景的结果。这些疗法为传统化疗提供了一种潜在的替代方案，标志着精准肿瘤学的重大进展。本系统评价使用PubMed、谷歌学术、科学Direct、EBSCO和科学公共图书馆（PLoS）等各种数据库，使用常规关键词和医学主题词（MeSH）关键词进行。纳入标准限于英文免费全文、人类研究以及2019年至2024年期间的出版物。排除标准包括非英文语言的出版物和2019年之前的出版物。共识别出26篇文章，经过质量评估后选择了12篇文章。
